.jpg)
.png)
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for nearly 18 million deaths in 2017 with 859,125 of those occurring in the United States – a number higher than death from all forms of cancer combined.(1) Unfortunately, this global number is anticipated to rise to over 22 million by 2030.
About one third of American adults have some form of CVD, with costs of the management of these conditions surpassing $351 billion between 2014 and 2015.(1)
Article By:
Preventative Cardiology Fellow
Lenox Hill Hospital
New York, NY
Director, Cardiovascular Health and Lipidology
Associate Professor of Medicine
Zucker School of Medicine
Sandra Atlas Bass Heart Hospital
North Shore University Hospital
Manhasset, NY
Diplomate, American Board of Clinical Lipidology
“In the long history of humankind (and of animal kind too) those who learned to collaborate and improvise most effectively have prevailed” ~ Charles R. Darwin
Article By:
Editor, LipidSpin
Medical Director, Lipid Clinic and Physician Advisor
Ascension Wisconsin All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology
As I write this, it is nearly impossible to address anything related to health care and medicine without mentioning COVID19. Indeed, this pandemic has effected changes most of us never imagined. Lives have been lost. Families have suffered. Unemployment is rampant. The tension between restoring the economy and respecting the virus is palpable. There remains much uncertainty.
Article By:
Past President, Southeast Lipid Association
Medical Director, Hometown Direct Care
Hometown Direct Consulting
Cherryville, NC
Diplomate, American Board of Clinical Lipidology
As an intern, in 1972, what I feared most was caring for an acute myocardial infarction (MI). Prior to the coronary care unit (CCU), developed in Kansas in the 1960’s, the mortality of an acute MI was 30% and subsequently dropped to 15% because of effective treatment of arrhythmias. Otherwise treatment was oxygen, morphine, listening to the patient, and providing support for the family.
Article By:
Past President, Northeast Lipid Association
Director, Cardiovascular Prevention
Christiana Care Health System
Newark, DE
Diplomate, American Board of Clinical Lipidology
I would like to welcome everyone to the Potpourri Edition of LipidSpin – brought to you this year as a joint effort between the Northeast and Southeast Lipid Associations. This is the first LipidSpin edition that I have the good fortune of introducing to you as President of the National Lipid Association.
Article By:
President, National Lipid Association
Professor and Vice Chair, Department of Clinical Pharmacy
Professor, Department of Family Medicine
University of Colorado Anschutz Medical Campus
Aurora, CO
View the September 2020 SWLA E-Newsletter by clicking here.
Regeneron Pharmaceuticals, Inc. today announced that the New England Journal of Medicine (NEJM) published positive results from the Phase 3 trial of evinacumab in 65 patients with homozygous familial hypercholesterolemia (HoFH).
The NLA is excited to share that we will host our first-ever virtual Scientific Sessions! Due to current travel restrictions and gathering limitations in the city of Chicago, the NLA has made the difficult decision to rescope our 2020 Scientific Sessions into a fully virtual conference held live on Thursday, December 10 – Saturday, December 12, 2020.
There will be a reduced meeting registration for the virtual conference at a discounted rate of only $299. Registration for the virtual sessions will open at the end of August.
View the August 2020 NELA E-Newsletter by clicking here.
August President's Message
Dr. Joseph Saseen takes a look ahead at what is to come for the NLA, including LipidPALOOZA in September!